CN114340732A - 普氏菌属制剂以及治疗慢性阻塞性肺部疾病(copd)和其他肺部疾病 - Google Patents

普氏菌属制剂以及治疗慢性阻塞性肺部疾病(copd)和其他肺部疾病 Download PDF

Info

Publication number
CN114340732A
CN114340732A CN202080058062.1A CN202080058062A CN114340732A CN 114340732 A CN114340732 A CN 114340732A CN 202080058062 A CN202080058062 A CN 202080058062A CN 114340732 A CN114340732 A CN 114340732A
Authority
CN
China
Prior art keywords
prevotella
histolytica
infection
mammal
melanogenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058062.1A
Other languages
English (en)
Chinese (zh)
Inventor
V·坦奈加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of CN114340732A publication Critical patent/CN114340732A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080058062.1A 2019-06-17 2020-06-17 普氏菌属制剂以及治疗慢性阻塞性肺部疾病(copd)和其他肺部疾病 Pending CN114340732A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
US62/862,186 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
CN114340732A true CN114340732A (zh) 2022-04-12

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058062.1A Pending CN114340732A (zh) 2019-06-17 2020-06-17 普氏菌属制剂以及治疗慢性阻塞性肺部疾病(copd)和其他肺部疾病

Country Status (11)

Country Link
US (1) US20220296657A1 (cg-RX-API-DMAC10.html)
EP (1) EP3983067A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022537178A (cg-RX-API-DMAC10.html)
KR (1) KR20220024466A (cg-RX-API-DMAC10.html)
CN (1) CN114340732A (cg-RX-API-DMAC10.html)
AU (1) AU2020295393A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021025416A2 (cg-RX-API-DMAC10.html)
CA (1) CA3143597A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022000029A2 (cg-RX-API-DMAC10.html)
MX (1) MX2021015711A (cg-RX-API-DMAC10.html)
WO (1) WO2020257248A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
EP4297762A1 (en) * 2021-02-26 2024-01-03 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
US20250325598A1 (en) * 2022-05-06 2025-10-23 The Regents Of The University Of Colorado, A Body Corporate Immunobiotics for preventing bacterial pneumonia and methods of using the same
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
WO2019051381A1 (en) * 2017-09-08 2019-03-14 Evelo Biosciences, Inc. EXTRACELLULAR VESICLES FROM PREVOTELLA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US20090257993A1 (en) * 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
RU2009133376A (ru) 2007-03-27 2011-05-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для введения пробиотиков
WO2011053653A2 (en) * 2009-10-30 2011-05-05 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
JP2014196260A (ja) * 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
US10465224B2 (en) * 2015-02-03 2019-11-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
KR20250161669A (ko) * 2015-09-09 2025-11-17 레비비코르 인코포레이션 이종 장기이식을 위한 멀티-형질전환 피그
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
WO2019004668A1 (ko) * 2017-06-30 2019-01-03 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
WO2019051381A1 (en) * 2017-09-08 2019-03-14 Evelo Biosciences, Inc. EXTRACELLULAR VESICLES FROM PREVOTELLA

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ETSUKO KURIMOTO，ET AL: ""IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice"", 《RESPIRATORY RESEARCH》, vol. 14, no. 1, pages 2 - 4 *
ROBERT VASSALLO，ET AL: ""Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes"", 《CLINICAL IMMUNOLOGY》, vol. 152, no. 1, pages 141 - 142 *
杨宝亮等主编: "《最新实用医学》", 30 June 2009, 黑龙江科学技术出版社, pages: 120 - 123 *
车晓文等: "《呼吸系统疾病现代诊断与治疗》", 30 September 2007, 天津科学技术出版社, pages: 70 - 72 *

Also Published As

Publication number Publication date
EP3983067A4 (en) 2023-06-14
JP2022537178A (ja) 2022-08-24
AU2020295393A1 (en) 2022-01-06
EP3983067A1 (en) 2022-04-20
CA3143597A1 (en) 2020-12-24
US20220296657A1 (en) 2022-09-22
BR112021025416A2 (pt) 2022-02-22
KR20220024466A (ko) 2022-03-03
MX2021015711A (es) 2022-02-03
WO2020257248A1 (en) 2020-12-24
CO2022000029A2 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
US9750802B2 (en) Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US20220296657A1 (en) Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions
RU2761636C2 (ru) Бактерия для применения в качестве пробиотика, употребляемого с пищей и в медицине
EP3369425B1 (en) Compositions comprising bacterial strains
EP3204024B1 (en) Compositions comprising bacterial strains
TWI733676B (zh) 包含細菌菌株之組合物
TW202120109A (zh) 使用普雷沃菌屬治療ｔｈ２介導的病症之組成物及方法
AU2004262446B2 (en) Method for inhibiting bacterial colonisation
Bibi et al. Evaluation of isolated probiotics on the efficacy of immune system in male and female Wistar rats
Elabbasy et al. Optimistic effects of dual nano-encapsulated probiotics on breeders laying performance, intestinal barrier functions, immunity and resistance against Salmonella Typhimurium challenge
Famularo et al. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease
Khosravi et al. Effect of Bacillus subtilis and Bacillus coagulans spores on induced allergic contact dermatitis in dogs
JP2024546437A (ja) 疾患を処置するための細菌株
JP2022155522A (ja) 免疫機能低下抑制剤及び免疫機能の低下抑制方法
IBRAEVA et al. SCIENCE & HEALTHCARE
Baier Interleukin-33: new insights into the crosstalk between the mucosal immune system and the gut microbiota
WO2021177432A1 (ja) 乳酸菌含有組成物
Danka Defining the roles of outer membrane proteins and host cathelicidins in uropathogenic Escherichia coli infection
Maslowski The role of GPR43 in the immune system: a novel connection between diet, gut microbiota and immune function
Nguyen A Study of Immune-Regulation of Microbiota Supernatant on Macrophage Function
Boots Factors influencing F18+ Escherichia coli receptor expression in weanling pigs
Hopwood-Courville The role of intestinal epithelial cell CD23 in food allergy
HK1240831A1 (en) Compositions comprising bacterial strains
HK1240831B (en) Compositions comprising bacterial strains
HK1209367B (en) Use of clostridium nexile in the treatment or prevention of rheumatoid arthritis or related diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination